During 1988-1991, 118 cases of culture-proven oropharyngeal Candida infection were seen in 436 HIV-positive patients. During 1988-1989, all but 1 of 29 cases of oropharyngeal candidosis were due to C. albicans, while in 1990-1991, 15 of 89 (16.8%) infections were due to species other than C. albicans. Non-albicans species included C. krusei (7 cases), C. parapsilosis (2), C. tropicalis (1) and Torulopsis glabrata (6). Eleven of the 16 patients were receiving chronic antifungal suppression therapy with fluconazole. All patients responded to oral antifungal therapy except 2, 1 of whom developed disseminated candidosis due to T. glabrata that was resistant to fluconazole. It is concluded that the prophylactic use of azoles to prevent fungal infections must be reconsidered and their efficacy compared with non-absorbable antifungal agents.